For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $8.49 in the prior trading day, Cullinan Therapeutics Inc (NASDAQ: CGEM) closed at $7.69, down -9.42%. In other words, the price has decreased by -$9.42 from its previous closing price. On the day, 0.82 million shares were traded. CGEM stock price reached its highest trading level at $8.57 during the session, while it also had its lowest trading level at $7.6531.
Ratios:
Our goal is to gain a better understanding of CGEM by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.83 and its Current Ratio is at 9.83. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On October 24, 2024, UBS started tracking the stock assigning a Buy rating and target price of $30.UBS initiated its Buy rating on October 24, 2024, with a $30 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 16 ’25 when Lynx1 Capital Management LP bought 150,000 shares for $8.86 per share. The transaction valued at 1,328,250 led to the insider holds 8,765,616 shares of the business.
Lynx1 Capital Management LP bought 51,500 shares of CGEM for $409,049 on Oct 15 ’25. The 10% Owner now owns 8,615,616 shares after completing the transaction at $7.94 per share. On Oct 17 ’25, another insider, Lynx1 Capital Management LP, who serves as the 10% Owner of the company, bought 32,217 shares for $7.84 each. As a result, the insider paid 252,565 and bolstered with 8,797,833 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CGEM now has a Market Capitalization of 454282080 and an Enterprise Value of 190319072.
Stock Price History:
The Beta on a monthly basis for CGEM is -0.04, which has changed by -0.5054662 over the last 52 weeks, in comparison to a change of 0.20772064 over the same period for the S&P500. Over the past 52 weeks, CGEM has reached a high of $17.50, while it has fallen to a 52-week low of $5.68. The 50-Day Moving Average of the stock is 8.80%, while the 200-Day Moving Average is calculated to be -4.87%.
Shares Statistics:
The stock has traded on average 833.82K shares per day over the past 3-months and 1059440 shares per day over the last 10 days, according to various share statistics. A total of 59.07M shares are outstanding, with a floating share count of 36.84M. Insiders hold about 37.64% of the company’s shares, while institutions hold 78.28% stake in the company. Shares short for CGEM as of 1760486400 were 6629787 with a Short Ratio of 7.95, compared to 1757894400 on 6181110. Therefore, it implies a Short% of Shares Outstanding of 6629787 and a Short% of Float of 12.979999000000001.
Earnings Estimates
The dynamic stock of Cullinan Therapeutics Inc (CGEM) is currently being evaluated by a team of 8.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.91, with high estimates of -$0.83 and low estimates of -$1.02.
Analysts are recommending an EPS of between -$3.31 and -$4.01 for the fiscal current year, implying an average EPS of -$3.67. EPS for the following year is -$3.62, with 7.0 analysts recommending between -$2.59 and -$4.4.
